Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of advanced/metastatic renal cell carcinoma (mRCC) in the first line.
While new drugs have expanded the treatment options, mRCC remains incurable, and most first-line patients relapse following treatment.
Significant opportunities remain for new therapies under development in this highly competitive market.
Capitalizing on our unique expertise in the mRCC market and in patient chart-based research, our mRCC syndicated study uses real world data to monitor the evolution of mRCC management.
Fill in the form to access an overview of our mRCC syndicated study including:
- Types of data collected
- Dates of research waves